Showing results (81-90 of 118) with videos related to
Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerJyoti D Patel, Mark A Socinski, Edward B Garon, et al.Clinical Lung Cancer|July 14, 2023
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never SmokedJ Nicholas Bodor, Jyoti D Patel, Heather A Wakelee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2013
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical OncologyJyoti D Patel, Lada Krilov, Sylvia Adams, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2011
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical OncologyNicholas J Vogelzang, Steven I Benowitz, Sylvia Adams, et al.Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.Oncology and Therapy|July 22, 2024
Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with ImmunotherapyRyan D Gentzler, John Guittar, Akash Mitra, et al.JCO Precision Oncology|September 7, 2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)Riha Vaidya, Joseph M Unger, Lu Qian, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2025
Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP StudyPhilip C Mack, Mary W Redman, Hanna Tukachinsky, et al.Scientific Reports|October 9, 2021
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancerStanley I Gutiontov, William Tyler Turchan, Liam F Spurr, et al.Cancer Discovery|February 26, 2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II TrialGregory J Riely, Joel W Neal, D Ross Camidge, et al.Pageof 12